Related Experiment Videos
Ventricular arrhythmias in heart failure
1Department of Medicine, Keio University, Tokyo, Japan.
The Keio Journal of Medicine
|March 1, 1996
Summary
In chronic heart failure management, focus shifts to longevity. Certain drugs like beta-blockers and ACE inhibitors show promise in preventing sudden cardiac death, likely through myocardial protection.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Chronic heart failure (CHF) management is evolving towards improving patient longevity.
- Sudden cardiac death (SCD) accounts for up to 50% of deaths in CHF patients.
- Ventricular arrhythmias in CHF may be markers of disease rather than direct predictors of SCD.
Purpose of the Study:
- To review current strategies in CHF management, emphasizing the shift towards longevity.
- To discuss the role of arrhythmias in CHF and their relation to SCD.
- To identify pharmacologic agents effective in preventing SCD in CHF patients.
Main Methods:
- Review of existing literature on CHF management and SCD.
- Analysis of the role of ventricular arrhythmias in CHF prognosis.
- Evaluation of drug classes demonstrated to reduce SCD in CHF.
Main Results:
- Pharmacologic augmentation of contractility or suppression of asymptomatic arrhythmias may be ineffective or harmful for SCD prevention.
- Amiodarone, beta-blockers, and angiotensin-converting enzyme (ACE) inhibitors have shown efficacy in preventing SCD in CHF.
- The exact mechanisms of these drugs in improving CHF prognosis are unclear, but myocardial protection is a likely factor.
Conclusions:
- The focus in CHF management is shifting from ventricular function to patient longevity.
- Certain medications, including amiodarone, beta-blockers, and ACE inhibitors, are crucial for preventing sudden cardiac death in chronic heart failure.
- Myocardial protective effects are likely key to the benefits of these drugs in improving heart failure outcomes.